Prescribing information

 

Resources designed to support KISQALI prescribers.

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Preview or download resources designed to support KISQALI prescribers. If you would like to get more information or receive copies of any materials, please contact a Novartis representative.

Treatment management

 

Your Choice with KISQALI logo

YOUR CHOICE WITH KISQALI

Your Choice is a dedicated support programme designed to facilitate monitoring of KISQALI patients in day-to-day practice.

Find out more Download guide

 

 

Preview of therapy management guide

THERAPY MANAGEMENT GUIDE

This guide provides information for healthcare professionals about how to use KISQALI, detailing posology, monitoring and managing adverse events.

Download

 

 

Patient materials

 

Preview of patient information booklet: KISQALI + AI

PATIENT INFORMATION BOOKLET: KISQALI + AROMATASE INHIBITOR (AI)

This booklet provides information for patients about what to expect from treatment with KISQALI + AI.

Download

 

 

Preview of patient information booklet: KISQALI + fulvestrant

PATIENT INFORMATION BOOKLET: KISQALI + FULVESTRANT

This booklet provides information for patients about what to expect from treatment with KISQALI + fulvestrant.

Download

 

 

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1

Reference

  1. KISQALI® (ribociclib) Summary of Product Characteristics.
HCP20-C019 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]